Molecular testing that changes decisions

Lung cancer treatment changed by EGFR testing

One mutation can change the first treatment decision. In lung cancer, molecular profiling may identify actionable drivers such as EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, or ERBB2 — allowing the oncology team to consider targeted therapy instead of a non-personalized approach.

Immunotherapy eligibility found by MSI/MMR testing

Molecular testing can reveal that the most important feature of a cancer is not only its organ of origin, but its biology. MSI-high / mismatch-repair-deficient tumors may be eligible for immune checkpoint inhibitor therapy in certain clinical settings.

Acute promyelocytic leukemia identified urgently

In hematologic malignancies, molecular testing is sometimes not only informative — it is urgent. Identifying the right fusion, such as PML::RARA, can change treatment on the same clinical pathway from the first day.

Leukemia monitoring after treatment

Molecular testing can help answer: Is the disease responding? Is resistance emerging? Is relapse becoming detectable before it is visible by routine methods?

A BRCA result changes prevention and family testing

Hereditary cancer testing can change care for the patient in front of us — and also identify relatives who may benefit from prevention, surveillance, or reassurance.

Lynch syndrome prevents future cancers

A hereditary cancer result can turn one diagnosis into a prevention opportunity for an entire family.

Peace of mind for relatives

Sometimes the most powerful result is not finding a mutation — it is giving a family member a clear answer that they did not inherit the known familial risk.

Low-risk NIPT reduces uncertainty

NIPT can provide early, non-invasive risk assessment for common chromosomal conditions, helping families and physicians decide whether reassurance, follow-up, genetic counseling, or diagnostic testing is appropriate.

A high-risk result changes pregnancy planning

NIPT does not replace diagnostic testing, but it can identify pregnancies that need earlier counseling and confirmatory evaluation such as CVS or amniocentesis.

Ending the diagnostic odyssey

For rare disease families, a molecular diagnosis can end years of uncertainty — converting a collection of symptoms into a named condition, a care plan, and reproductive-risk information.

Management changed by a genetic diagnosis

Rare disease testing is not only about naming a condition. It can change what clinicians monitor, what treatments they avoid, and what the family should expect next.

PGT-M avoids recurrence of a severe inherited disease

For some families, reproductive genetic testing changes the story from recurrence risk to reproductive choice.

A balanced translocation explains pregnancy loss

Chromosomal testing can explain repeated loss, clarify recurrence risk, and help couples choose the safest next step.

Avoiding severe chemotherapy toxicity with DPYD testing

Pharmacogenomics can identify patients at increased risk of serious drug toxicity before treatment starts — allowing clinicians to consider safer dosing or alternatives.

Choosing safer medications

The right medication is not always only about the diagnosis. Sometimes it is also about the patient's genes.

Insight that stays in its lane

Wellness genomics can support informed conversations about traits, ancestry, selected health predispositions, and lifestyle-related insights — but medical decisions should be made with a qualified clinician and confirmed through validated clinical testing when needed.